Navigation Links
Bellicum Pharmaceuticals Raises $34.4 Million in a Series B Financing
Date:1/7/2014

HOUSTON, Jan. 7, 2014 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. announced today that it has completed a second and final closing of its Series B financing, securing an additional $14.7 million and bringing the total raised in the round to $34.4 million. Current investors provided the additional funding, including AVG Ventures and Remeditex Ventures.

The funding will be used to expand clinical development of Bellicum's lead cellular immunotherapy product candidates.

"Bellicum is well positioned within the highly promising field of cellular immunotherapy with a technology that provides control over cells after they have been administered to the patient," said Bellicum CEO Tom Farrell. "This funding will be used to advance our two clinical programs in leukemia/lymphoma and prostate cancer, and launch studies in additional indications where there is urgent need for safer and more effective cell therapies."

Bellicum's two lead clinical development programs utilize the Company's unique ability to control cell therapies once inside the body. BPX-501 T cells contain the Company's CaspaCIDe™ gene "safety switch," enabling physicians to eliminate transplanted cells in the event they become harmful to the patient. The product is being evaluated in a Phase I/II study to reduce or eliminate Graft versus Host Disease in cancer patients undergoing hematopoietic stem cell transplant.

BPX-201 dendritic cells contain the Company's DeCIDe® gene "on switch," which enables physicians to strategically target immune activation for a more potent anti-tumor effect. It is being evaluated in a Phase I clinical trial in patients with metastatic castrate-resistant prostate cancer.

About Bellicum Pharmaceuticals

Bellicum is dedicated to developing safer and more effective cell therapies to treat cancers and other serious, life-threatening diseases. The Company's cel
'/>"/>

SOURCE Bellicum Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Jazz Pharmaceuticals to Present at J.P. Morgan Healthcare Conference on January 13
2. Avanir Pharmaceuticals to Present at J.P. Morgan 32nd Annual Healthcare Conference
3. ANI Pharmaceuticals Enters Development Agreement for Generic Drug Product with Sterling Pharmaceutical Services
4. Arena Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
5. Isis Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
6. Inovio Pharmaceuticals to Present at Biotech Showcase 2014 Investor Conference
7. Global Radiopharmaceuticals Market Report 2013 - 2018
8. Pre-Market Update: MGT Capital Investments, National American University Holdings and Actinium Pharmaceuticals
9. ANI Pharmaceuticals Acquires 31 Generic Drug Products from Teva Pharmaceuticals
10. New Appointments, and Share Price Movements - Research Report on Humana, Illumina, Edwards Lifesciences, Aegerion Pharmaceuticals, and CytRx
11. Taiwan Spends a High Percentage of its Healthcare Budget on Pharmaceuticals, but Second Generation Healthcare Reform is Transforming the Market Landscape
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Colo. , July 29, 2014 New ... (MARC) which could allow physicians to see and assess ... hold promise, according to study authors who released their ... 11 th Annual Meeting in Colorado ... to advance the field of neurointervention, a specialty that ...
(Date:7/29/2014)... 2014 /PRNewswire-iReach/ -- MHG Medical Management Services, a ... Medical Equipment and X-ray Annual Inspection & ... to the cruise industry,s unique requirements.  MHG Medical,s ... propose that they should develop a new service. ... intended to create standardized processes and raise standards, ...
(Date:7/29/2014)... July 29, 2014  Neurocrine Biosciences, Inc. (Nasdaq: ... report its second quarter 2014 financial results after the ... will then host a live conference call and webcast ... update Thursday morning, August 7, 2014 at 8:00 a.m. ... can access the live conference call by dialing 866-952-1907 ...
Breaking Medicine Technology:New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3MHG Medical Management Services Aims to Change Cruise Industry Standard With New Equipment Maintenance Program 2Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2
... NanoBio Corporation,announced today that it has seen ... 2 study of NB-002, a topical lotion for ... results clearly,justify completing the study, according to NanoBio ... grow out a clear nail after,successfully treating the ...
... March 20 PLC Systems Inc.,(Amex: PLC ... approval from,the U.S. Food and Drug Administration (FDA) ... study the effectiveness of the Company,s RenalGuard,Therapy(TM) and ... Mark R. Tauscher, President and Chief Executive ...
Cached Medicine Technology:NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis 2PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S. 2PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S. 3PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S. 4
(Date:7/30/2014)... According to the Nasal Polyps Treatment Miracle book review ... teaches people how to cure their nasal polyps ... the horrible truth about conventional treatments for nasal polyps. ... people will learn how to prevent symptoms related to ... , Nasal Polyps Treatment Miracle, as it is reviewed now ...
(Date:7/30/2014)... San Francisco, CA (PRWEB) July 30, 2014 ... charge capture and physician communication, launched an Observation ... performed in the hospital. pMD’s cardiology customers are ... and optimize revenue for their test interpretations for ... provider interprets tests in the hospital, the cardiology ...
(Date:7/29/2014)... Paul Mata, CEO of ‘Create Indestructible Wealth,’ ... 30 Days” E-book. The e-book includes a myriad of fast ... cash. Examples include downloading and utilizing specific phone apps ... people monetize the assets they didn't know they had like ... find in their garage. , After reading the e-book, ...
(Date:7/29/2014)... Ireland (PRWEB) July 30, 2014 Dignity ... the successful completion of a Phase I trial with ... (DGLA). , This study was a randomized, placebo-controlled, double-blind, ... assess the safety, pharmacokinetics and effect of food on ... the benign safety profile of DGLA following both single ...
(Date:7/29/2014)... (EA) a form of acupuncture where a ... acupuncture needles produces significant improvements in fatigue, ... weeks for early stage breast cancer patients experiencing ... inhibitors (AIs) to treat breast cancer. The results ... led by researchers at the Perelman School of ...
Breaking Medicine News(10 mins):Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 2Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 3Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 2Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 3Health News:Create Indestructible Wealth Launches Innovative E-Book: “Realistic Ways to Make More Money in 30 Days” 2Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 3
... markets Aricept with Pfizer Inc. Aricept is already approved in ... but at present it was being tested in patients with ... Alzheimer's disease. ,But the shocking results show that ... clinical trial held at Japan's Eisai Co. ,There ...
... Dr Charles Reynolds at the University of Pittsburgh which was ... , The study’s main aim was to analyze the effect ... It is one of the longest studies ever in ... for longer periods, perhaps even for life, in patients who ...
... increasing number of addicts. Health authorities are warning of the ... with the consequences. ,Statistics show that about one ... Vincent's Hospital has recorded a five-fold increase in patients suffering ... in Australia. , The reason being that ice ...
... condition that affects millions of people. Scientists at the University ... leading to eczema and asthma. ,This gene produces ... outermost layers of the skin. It prevents bacteria and viruses ... to prevent the skin from drying. Reduction or absence of ...
... soon going to have more up market looking// medical stores ... supply free medicines to the patients., ,Apparently the ... ‘swanky medical stores’. These will be located at the entrance ... (BPL)’ card holders..., ,Mr Ashok said that these ...
... approval to formation of a Health Task Force for India.//, ... in the health sector in India which includes doctors, nurses ... commission on macroeconomics and health in its report,” a statement ... were also growing opportunities with India emerging as a major ...
Cached Medicine News:Health News:Drugs Are Effective In Treating Depression and Preventing Recurrence 2Health News:Gene That Causes Dry Skin, Identified 2
... utilizes allele-specific primer combinations in the PCR ... that only primers whose sequence is completely ... converted by the polymerase into PCR products. ... product. Using the Biotest SSP Kit Systems, ...
... The freezer is constructed with built-in bags ... the plasma bags are placed without contacting the ... and heavy inserts. This device ensures easy handling ... immersed plasma bags so that the relatively hot ...
Helmer offers Plasma Storage Freezer lines, the i.Series ipf 125-8. It is Designed to complement Blood Bank Refrigerators, it freezers offer outstanding features, including programmable defrost tim...
Plasma Blast Chest Freezer -50C - 8098/8091 maintains a -50C (-58F) temperature to rapidly freeze single donor, apheresed, and fresh frozen plasma. Rapid freezing also preserves Factor VIII. Full loa...
Medicine Products: